Details for Patent: 6,451,807

Title:	Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
Abstract:	The present invention relates to highly selective phosphodiesterase (PDE) enzyme inhibitors and to their use in methods of treating sexual dysfunction in individuals suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction.
Inventor(s):	Emmick; Jeffrey T. (Plainfield, IN), Ferguson; Kenneth M. (Bothell, WA), Pullman; William E. (Carmel, IN), Whitaker; John S. (Woodinvill, WA)
Assignee:	Lilly Icos, LLC. (Wilmington, DE)
Filing Date:	Apr 26, 2000
Application Number:	09/558,911
Claims:	1. A method of treating sexual dysfunction in an individual suffering from a retinal disease comprising administering an oral dosage form comprising about 1 to about 20 mg of a selective PDE5 inhibitor having (i) at least a 100-fold differential in IC.sub.50 values for the inhibition of PDE5 versus PDE6, (ii) at least 1000-fold differential in IC.sub.50 values for the inhibition of PDE5 versus PDE1c, (iii) an IC.sub.50 less than 10 nM, and (iv) a sufficient bioavailability to be effective in about 1 to about 20 mg unit oral dosages. 2. The method of claim 1 wherein the retinal disease is diabetic retinopathy. 3. The method of claim 1 wherein the retinal disease is retinitis pigmentosa. 4. A method of treating sexual dysfunction in an individual suffering from a condition selected from the group consisting of class 1 congestive heart failure, a myocardial infarction within 90 days before onset of the sexual dysfunction treatment, and combinations thereof comprising administering an oral dosage from comprising about 1 to about 20 mg of a selective PDE5 inhibitor having (i) at least a 100-fold differential in IC.sub.50 values for the inhibition of PDE5 versus PDE6, (ii) at least 1000-fold differential in IC.sub.50 values for the inhibition of PDE5 versus PDE1c, (iii) an IC50 less than 10 nM, and (iv) a sufficient bioavailability to be effective in about 1 to about 20 mg unit oral dosages. 5. The method of claims 1 or 4 wherein the oral dosage form comprises about 5 mg, about 10 mg, or about 20 mg, of a selective PDE5 inhibitor. 6. The method of claim 1 or 4 wherein the maximum dosage of the selective PDE5 inhibitor is about 20 mg per 24-hour period. 7. The method of claim 1 or 4 wherein the selective PDE5 inhibitor has the structure ##STR15##